DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours
Across seven tumour types including endometrial, cervical and ovarian cancers, trastuzumab deruxtecan shrank tumours in about 37 percent of patients overall and 61 percent of those with the highest HER2 expression, leading to a tumour-agnostic approval.
Overview
Phase 2 study of 267 patients with previously treated HER2-expressing (immunohistochemistry 3+ or 2+) advanced solid tumours in seven cohorts (endometrial, cervical, ovarian, bladder, biliary, pancreatic and other) treated with trastuzumab deruxtecan 5.4 mg/kg.
Objective response was 37.1 percent overall and 61.3 percent in immunohistochemistry 3+ tumours, with median duration of response 11.3 and 22.1 months respectively; endometrial (57.5 percent) and cervical (50.0 percent) cohorts responded best. Interstitial lung disease occurred in 10.5 percent.
- Objective response 37.1 percent overall; 61.3 percent in immunohistochemistry 3+.
- Endometrial cohort response 57.5 percent; cervical 50.0 percent.
HER2 immunohistochemistry is now worth doing in advanced gynaecological and other cancers, since trastuzumab deruxtecan is approved for HER2 3+ solid tumours after prior therapy.
- Single-arm across heterogeneous tumours; responses in 2+ tumours were modest (27 percent).
- Interstitial lung disease including fatal cases.
Similar pages
not linked directly; found by shared links- IdeaHER2 ADCs as standard for HER2-positive serous endometrial cancer
Shares DESTINY-PanTumor02, Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab deruxtecan.
- Key paperCarboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Journal of Clinical Oncology, Trastuzumab.
- Key paperDESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer
Shares Journal of Clinical Oncology, Trastuzumab deruxtecan, Trastuzumab.
- Key paperGOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma
Shares Uterine carcinosarcoma, Journal of Clinical Oncology.
- PersonFunda Meric-Bernstam
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan.
- Key paperMolecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Journal of Clinical Oncology.
- Key paperPhase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma
Shares Journal of Clinical Oncology, Trastuzumab.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab deruxtecan, Trastuzumab.